MAK7049

MAK7049 is a preclinical-stage small molecule drug candidate developed by MAK Scientific for oral administration. It is designed to modulate the endocannabinoid system, a complex cell-signaling network involved in regulating various physiological processes. While the specific molecular target and primary therapeutic indication for MAK7049 have not been publicly disclosed, the compound is part of a pipeline focused on addressing conditions such as chronic liver disease, metabolic disorders, neurodegenerative diseases, and inflammatory pain. The developer, MAK Scientific, specializes in targeting cannabinoid receptors (CB1, CB2) and enzymes involved in endocannabinoid metabolism, such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL).